000178299 001__ 178299
000178299 005__ 20240229133804.0
000178299 0247_ $$2doi$$a10.3390/cancers13246269
000178299 0247_ $$2pmid$$apmid:34944892
000178299 037__ $$aDKFZ-2021-03246
000178299 041__ $$aEnglish
000178299 082__ $$a610
000178299 1001_ $$aDaskalakis, Michael$$b0
000178299 245__ $$aPotential to Improve Therapy of Chronic Myeloid Leukemia (CML), Especially for Patients with Older Age: Incidence, Mortality, and Survival Rates of Patients with CML in Switzerland from 1995 to 2017.
000178299 260__ $$aBasel$$bMDPI$$c2021
000178299 3367_ $$2DRIVER$$aarticle
000178299 3367_ $$2DataCite$$aOutput Types/Journal article
000178299 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1641066338_26314
000178299 3367_ $$2BibTeX$$aARTICLE
000178299 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000178299 3367_ $$00$$2EndNote$$aJournal Article
000178299 520__ $$aTyrosine kinase inhibitors (TKI) substantially improved chronic myeloid leukemia (CML) prognosis. We aimed to describe time period- and age-dependent outcomes by reporting real-world data of CML patients from Switzerland.Population-based incidence, mortality, and survival were assessed for four different study periods and age groups on the basis of aggregated data from Swiss Cantonal Cancer Registries.A total of 1552 new CML cases were reported from 1995 to 2017. The age-standardized rate (ASR) for the incidence remained stable, while the ASR for mortality decreased by 50-80%, resulting in a five-year RS from 36% to 74% over all four age groups. Importantly, for patients <60 years (yrs), the five-year RS increased only in earlier time periods up to 92%, whereas for older patients (+80 yrs), the five-year RS continued to increase later, however, reaching only 53% until 2017.This is the first population-based study of CML patients in Switzerland confirming similar data compared to other population-based registries in Europe. The RS increased significantly in all age groups over the last decades after the establishment of TKI therapy. Interestingly, we found a more prominent increase in RS of patients with older age at later observation periods (45%) compared to patients at younger age (10%), implicating a greater benefit from TKI treatment for elderly occurring with delay since the establishment of TKI therapy. Our findings suggest more potential to improve CML therapy, especially for older patients.
000178299 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000178299 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000178299 650_7 $$2Other$$aCML
000178299 650_7 $$2Other$$aincidence
000178299 650_7 $$2Other$$amortality
000178299 650_7 $$2Other$$arelative survival
000178299 650_7 $$2Other$$atyrosine kinase inhibitor
000178299 7001_ $$aFeller, Anita$$b1
000178299 7001_ $$aNoetzli, Jasmine$$b2
000178299 7001_ $$00000-0001-8761-2066$$aBonadies, Nicolas$$b3
000178299 7001_ $$0P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0$$aArndt, Volker$$b4$$udkfz
000178299 7001_ $$aBaerlocher, Gabriela Maria$$b5
000178299 7001_ $$aThe Nicer Working Group$$b6
000178299 773__ $$0PERI:(DE-600)2527080-1$$a10.3390/cancers13246269$$gVol. 13, no. 24, p. 6269 -$$n24$$p6269$$tCancers$$v13$$x2072-6694$$y2021
000178299 909CO $$ooai:inrepo02.dkfz.de:178299$$pVDB
000178299 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000178299 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000178299 9141_ $$y2021
000178299 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCERS : 2019$$d2021-05-04
000178299 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-05-04
000178299 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-05-04
000178299 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2021-05-04
000178299 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-05-04
000178299 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-05-04
000178299 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2021-05-04
000178299 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-05-04
000178299 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2021-05-04
000178299 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2021-05-04
000178299 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-05-04
000178299 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-05-04
000178299 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-05-04
000178299 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-05-04
000178299 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-05-04
000178299 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-05-04
000178299 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCERS : 2019$$d2021-05-04
000178299 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-05-04
000178299 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-05-04
000178299 9201_ $$0I:(DE-He78)C071-20160331$$kC071$$lC071 Cancer Survivorship$$x0
000178299 980__ $$ajournal
000178299 980__ $$aVDB
000178299 980__ $$aI:(DE-He78)C071-20160331
000178299 980__ $$aUNRESTRICTED